Stacie Hudgens

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Measuring the side effects of taxane therapy in oncology

David Cella, Amy H. Peterman, Stacie Hudgens et al. · Cancer · 2003 · 282 citations

Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study

Elizabeth A. Hahn, G. Alastair Glendenning, Mark Sorensen et al. · Journal of Clinical Oncology · 2003 · 208 citations

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Arndt Vogel, Shukui Qin, Masatoshi Kudo et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 139 citations

Patient-reported Outcomes, Hepatology, Medicine +10

Atherosclerotic risk factor reduction in peripheral arterial disease

Mary Mcdermott, Elizabeth A. Hahn, Philip Greenland et al. · Journal of General Internal Medicine · 2002 · 130 citations · Full text

Cardiovascular Disease, Peripheral Artery Disease, Arterial Disease +6